VEGFA and metastatic colorectal cancer: “Trifluridine and tipiracil (marketed by Taiho Oncology, Inc. as LONSURF) in combination with bevacizumab received FDA approval on August 2, 2023, for treating metastatic colorectal cancer (mCRC) that was previously managed with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, as well as anti-VEGF biological therapy.